Skip to main content

Advertisement

Tables 3 Proliferative capacity and lifespan of TCCs on antioxidant supplementation

From: SENIEUR status of the originating cell donor negates certain ‘anti-immunosenescence’ effects of ebselen and N-acetyl cysteine in human T cell clone cultures

Clone (Age of the donor) Initial PD Concentration Average PD per week Cumulative PD achieved at the end of lifespan in culture
400-23 (26 year old donor) 34.5 Control 0.7 ± 0.1 44.7 ± 0.3*
30 μM Ebselen 1.2 ± 0.2 56.2 ± 0.4*
385-7 (45 year old donor) 31.0 Control 1.0 ± 0.1 44.4 ± 0.3*
30 μM Ebselen 1.4 ± 0.4 50.8 ± 0.4*
399-37 (80 year old donor) 31.1 Control 1.2 ± 0.2 45.0 ± 0.4
   30 μM Ebselen 1.2 ± 0.1 44.6 ± 0.3
Clone (Age of the donor) Initial PD Concentration Average PD per week Cumulative Pd achieved at the end of lifespan in culture
400-23 (26 year old donor) 34.5 Control 0.7 ± 0.1 44.7 ± 0.3*
7.5 mMNAC 1.2 ± 0.2 56.1 ± 0.3*
385-7 (45 year old donor) 31.0 Control 1.0 ± 0.1 44.4 ± 0.3*
7.5 mMNAC 1.4 ± 0.4 55.8 ± 0.4*
399-37 (80 year old donor) 31.1 Control 1.1 ± 0.2 44.2 ± 0.5
7.5 mMNAC 0.9 ± 0.2 42.3 ± 0.4
  1. Effect of Ebselen or NAC supplementation on the proliferative capacity and lifespan of CD4+ TCCs derived from healthy 26, 45 or 80 year old donors.
  2. Data of 26 and 45 year old donors are published data from [10]. *Significantly higher cumulative PDs in supplemented (+) clones compared to controls (-). n = 3 pooled TCCs for each age group.